Microfluidic BoNT Detection via Enzymatic Cleavage and Electrophoresis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current assays for detecting Botulinum Neurotoxin (BoNT) are inadequate due to their limited sensitivity, inability to distinguish between active and inactive light chain forms, and lack of serotype specificity, which hinders effective diagnostics and therapeutic interventions.

Innovation Solution

A microfluidic device-based enzymatic activity assay using a substrate molecule with a SNAP25 sequence that is cleaved by BoNT, incorporating a reporter moiety and purification tag, allowing for detection of active BoNT through electrophoretic separation and elution time analysis, enabling serotype-specific detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If mouse bioassay is used for detecting BoNT, then sensitivity is improved (LOD ~0.01 ng/mL), but time consumption increases (>4 days required) and animal population requirements increase

Engineering Contradiction:

Improvedetection sensitivityVSAvoidassay time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent replaces the biological mouse bioassay system with an in vitro enzymatic activity assay system. The assay uses purified substrate molecules containing SNAP-25 sequences that are cleaved by BoNT light chain in a controlled in vitro environment, eliminating the need for live animal observation while maintaining detection sensitivity through specific enzymatic activity measurement.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces purified substrate molecules containing SNAP-25 sequences as intermediaries between the BoNT toxin and the detection system. These substrates specifically bind and are cleaved by active BoNT light chain, providing a direct measurable signal that replaces the indirect observation of animal symptoms and death.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If conventional immunoassay formats are used, then assay speed is improved, but sensitivity and ability to detect active toxin forms deteriorates

Engineering Contradiction:

Improveassay speedVSAvoiddetection sensitivity and active form discrimination

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent applies local quality by designing substrates with specific SNAP-25 sequences that are cleaved only by active BoNT light chain. The substrate contains a specific recognition sequence (Gln197-Gly206) that matches the natural BoNT cleavage site, ensuring that only enzymatically active toxin can produce the cleavage signal, thereby distinguishing active from inactive forms.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the detection parameter from antibody binding (immunoassay) to enzymatic cleavage activity. By measuring the presence of cleaved substrate fragments through electrophoretic separation, the assay directly detects functional enzymatic activity rather than merely detecting toxin presence, thereby improving sensitivity for active toxin forms.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If general BoNT detection assays are used, then broad detection capability is improved, but serotype specificity deteriorates

Engineering Contradiction:

Improvedetection capabilityVSAvoidserotype specificity

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent applies segmentation by designing different substrate variants, each containing SNAP-25 sequences specific to different BoNT serotypes. For example, substrates with sequences cleaved by BoNT/A (Gln197-Gly206), BoNT/C (Glu182-Val191), or BoNT/E (Glu182-Val191) can be used to specifically detect each serotype, allowing differentiation while maintaining broad detection capability.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a sensitive, rapid, and serotype-specific method for detecting active BoNT, improving diagnostic accuracy and therapeutic intervention by distinguishing between active and inactive toxin forms.

Implementation Method 1

the target agent, if present in the sample, cleaves the substrate molecule to produce cleaved reaction products

Methodology Applied

Scientific EffectEnzymatic cleavage: Enzyme

Implementation Method 2

determining an electrophoretic mobility of the reporter tag

Methodology Applied

Scientific EffectElectrophoresis: Electrophoresis

Data Source

PatentUS8871496B1Methods, microfluidic devices, and systems for detection of an active enzymatic agent

Publication Date: 2014.10.28 SANDIA NAT LAB

AI summary

Embodiments of the present invention provide methods, microfluidic devices, and systems for the detection of an active target agent in a fluid sample. A substrate molecule is used that contains a sequence which may cleave in the presence of an active target agent. A SNAP25 sequence is described, for example, that may be cleaved in the presence of Botulinum Neurotoxin. The substrate molecule includes a reporter moiety. The substrate molecule is exposed to the sample, and resulting reaction products separated using electrophoretic separation. The elution time of the reporter moiety may be utilized to identify the presence or absence of the active target agent.